Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial.
about
Induction and characterization of anti-tumor endothelium immunity elicited by ValloVax therapeutic cancer vaccine.Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cellsImmunotherapy for pancreatic cancer.Pancreatic cancer: Update on immunotherapies and algenpantucel-L.Immunogenicity and safety of xenogeneic vascular endothelial growth factor receptor-2 DNA vaccination in mice and dogs.A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer.Trial watch: DNA-based vaccines for oncological indicationsCancer Immunotherapy: Priming the Host Immune Response with Live Attenuated
P2860
Q33709802-E59F5771-6F06-4763-904D-71566579475BQ33833475-3F9A5689-6BAF-418C-8488-93817F4A0DF7Q38722325-02787F67-98B1-494E-9A61-6DE7A5BD62ECQ40261599-3FD84A25-BC9C-4F5A-936E-056583AE6642Q42576477-C1E2FEC9-A41E-4AD9-AFE9-9F2C700A4076Q52597561-1E6064ED-CA26-4847-929D-041F2F5BB5D1Q56893452-07EEC2D7-08C0-4376-8D9C-F99F3EC6029AQ57300412-3C1542E9-ADCD-4C63-A306-64AD6678CD1E
P2860
Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Anti-angiogenic activity of VX ...... ebo-controlled, phase 1 trial.
@ast
Anti-angiogenic activity of VX ...... ebo-controlled, phase 1 trial.
@en
type
label
Anti-angiogenic activity of VX ...... ebo-controlled, phase 1 trial.
@ast
Anti-angiogenic activity of VX ...... ebo-controlled, phase 1 trial.
@en
prefLabel
Anti-angiogenic activity of VX ...... ebo-controlled, phase 1 trial.
@ast
Anti-angiogenic activity of VX ...... ebo-controlled, phase 1 trial.
@en
P2093
P2860
P50
P1433
P1476
Anti-angiogenic activity of VX ...... cebo-controlled, phase 1 trial
@en
P2093
Alexis Ulrich
Andreas G Niethammer
Anne-Valerie Keller
Christine Leowardi
Frank Pianka
Friedrich H Schmitz-Winnenthal
Heinz Lubenau
Jürgen Weitz
Klaus M Breiner
Lars Grenacher
P2860
P304
P356
10.1080/2162402X.2014.1001217
P577
2015-03-16T00:00:00Z